Recent Updates
Recently added Catalysts
ZLAB Positive Sentiment

Zai Lab’s Zocilurtatug Pelitecan (Zoci, Formerly ZL-1310) Demonstrates High Response Rates, Encouraging Durability and Well-Tolerated Safety Profile in First-Line Extensive-Stage Small Cell Lung Cancer

Friday, October 23, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Zai Lab announced promising results from its Phase 1b trial of zocilurtatug pelitecan (Zoci) for extensive-stage small cell lung cancer. The treatment, used with atezolizumab and carboplatin, showed high response rates and encouraging durability. The findings will be presented at the ESMO Congress 2026.

Market Sentiment Analysis

POSITIVE FACTORS

  • High response rates observed in the trial.
  • Encouraging durability of treatment effects.
  • Well-tolerated safety profile reported.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+64%
120-day peak, hindsight
Typical move
2.3%
average across 15 past catalysts
Cash runway
~27 mo
Low dilution risk
Lead asset
ZL-1310
Phase 3 · Extensive-Stage Small Cell Lung Cancer

Full Press Release Details

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovation-driven, global biopharma company, today shared the first data from a global Phase 1b clinical trial evaluating zocilurtatug pelitecan (zoci, formerly ZL-1310) in combination with atezolizumab with and without carboplatin as first-line treatment for extensive-stage small cell lung cancer (ES-SCLC). The data will be presented at the European Society for Medical Oncology (ESMO) Congress 2026 in

Frequently Asked Questions

What is zocilurtatug pelitecan?

Zocilurtatug pelitecan, also known as Zoci, is a treatment for small cell lung cancer.

What were the results of the Phase 1b trial?

The trial showed high response rates and encouraging durability.

When will the trial data be presented?

The data will be presented at the ESMO Congress 2026.

What is the safety profile of Zoci?

Zoci demonstrated a well-tolerated safety profile in the trial.

ShareAdd on Google
Tags: ZLAB zocilurtatug small cell lung cancer Phase 1b trial atezolizumab
Last updated: Oct 23, 2026

Biotech snapshot

Cash runway
$618M liquidity · $21M/mo burn
~27 mo
Low dilution risk
Lead asset
ZL-1310Phase 3
Extensive-Stage Small Cell Lung Cancer →

Catalyst track record

+64%
best trade around ZLAB's most recent catalyst

Peak hindsight return over a 120-day window, across 15 tracked FDA/PDUFA catalysts for ZLAB.

See every catalyst's timing & PoA →